[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]
Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi
2019, Cilt 33, Sayı 2, Sayfa(lar) 089-093
[ Turkish ] [ Tam Metin ] [ PDF ]
The Results of Intravitreal Bevacizumab Injection by Macular Edema Associated with Retina Ven Obstruction
Yavuz ORUÇ1, Berrak ŞEKERYAPAN GEDİZ2
1Fethi Sekin Şehir Hastanesi, Göz Kliniği, Elazığ, TÜRKİYE
2Ulucanlar Göz Eğitim ve Araştırma Hastanesi, Göz Kliniği, Ankara, TÜRKİYE
Keywords: Retinal vein occlusion, macular edema

Objective: To evaluate visual acuity and central foveal thickness changes after bevacizumab intravitreal injection in the treatment of macular edema due to retinal vein occlusion.

Materials and Methods: In this retrospective study, 21 eyes of 21 patients who underwent bevacizumab intravitreal injection with diagnosis of macular edema due to retinal vein occlusion were examined. Three doses of intravitreal 1.25mg / 0.05ml bevacizumab injection was applied to the patients with one month intervals. Visual acuity (VA), central foveal thickness (CFT) and complications were recorded. The t-test was used to compare the data and P<0.05 was considered as statistically significant.

Results: The mean foveal thickness of the patients before injection was 548.0±227.8 μm, while it was 272.8±128.6 μm in the first month and 269.6±125.7 μm in the third month after injection. When compared with preoperative central foveal thickness, a decrease in the thickness of the central fovea was observed in the 1st and 3rd month after the treatment. All these reductions in CFT were statistically significant (P<0.05). The mean visual acuity of the patients before the injection was found as 0.72±0.45 logMAR (0.10–2.0) and 0.39±0.41 logMar (0.0–1.1) at the 1st month after injection and 0.41±0.38 logMar at the 3rd month (range: 0.0–1.3).

Conclusion: There was a statistically significant increase in best corrected visual acuity (BCVA) at the 1st and 3rd months after injection when compared with pre-injection values (P< 0.05).


[ Turkish ] [ Tam Metin ] [ PDF ]
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]